This is a news story, published by Investor's Business Daily, that relates primarily to NVS news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novartis stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest core earnings news, stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
NovartisInvestor's Business Daily
•Health
Health
83% Informative
Novartis ( NVS ) reported core earnings of $ 1.98 per share on $13.15 billion in fourth-quarter sales.
Entresto, the company's biggest moneymaker, generated $2.18 billion in sales, growing 33% .
The patent protecting the heart failure treatment is set to expire on July 15 .
VR Score
90
Informative language
94
Neutral language
48
Article tone
formal
Language
English
Language complexity
31
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links
